Luisa Iruela-Arispe named co-leader of the TEAM Program at Lurie Comprehensive Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Luisa Iruela-Arispe, a vascular biologist, was named co-leader of the Tumor Environment and Metastasis Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. 

The goal of the TEAM Program is to elucidate how interactions between tumor cells, immune cells, and components of the host stromal microenvironment impact tumor development and progression.

Iruela-Arispe is chair of the Department of Cell and Developmental Biology and the Stephen Walter Ranson Professor. Her research focuses on the signaling pathways that regulate vascular morphogenesis during development and pathological settings. Her cancer research interests include the molecular mechanisms that result in the emergence of angiosarcomas and the cross-talk between endothelial and tumor cells in the process of metastasis.

In collaboration with TEAM co-leader, Hidayatullah Munshi, she will help advance efforts to translate basic science discoveries from the TEAM Program into clinical practice.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login